COVID-19 Initiatives
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
Potential source of financing/partnership
2
For information only
3
4
Sponsor(s)InitiativeDeadlinePurposeValueApplication details
5
NIAID Omnibus
DMID
Solicitation HHS-NIH-NIAID-BAA2020-1April 9, 2020
Research Area 003: Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
Research Area 004 - Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases

Research Area 005 - Advanced Development of Diagnostics for Biothreats and Emerging Infectious Diseases
3 or more awards across Research Area 003 and 004 for a total cost of up to $11.5 million for the non-severable base work across all contracts (direct and indirect costs combined). The total performance period proposed should not exceed five (5) years.

1 or more awards across Research Area 003 and 004 for a total cost of up to $2 million for the non-severable base work across all contracts (direct and indirect costs combined). The total performance period proposed should not exceed five (5) years.
6
BARDA (Biomedical Advanced Research and Development Authority)Solicitation BAA-18-100-SOL-000032020, April 30COVID-19-related funding. Areas of interest include:
7.7 Emerging Diseases Diagnostics
7.7.1 Diagnostic Assay for human coronaviruses using existing FDA-cleared
platforms
7.7.2 Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus
7.7.3 Diagnostic Assay for detection of COVID-19 disease (SARS-CoV-2 infection)
9.2 COVID-19 Therapeutics
9.3 Immunomodulators or therapeutics targeting lung repair
9.4 Innovative approaches to improve clinical trial execution for hospitalized
influenza patients
9.5 Pre-exposure and Post-exposure Prophylaxis
p62:
 Quad Chart/White Paper (Stage 1)
 Full Proposal (Stage 2)
7
NIH/NIAIDRFA-AI-20-028 Partnerships for Countermeasures against Select PathogensLOI due May 20, Grant due June 29RFA-AI-20-028 (R01 Clinical Trials Not Allowed)
This FOA solicits research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.
Recommended budget for direct costs of up to $750,000 per year may be requested. Applicants may also request up to an additional $300,000 in the first year of the award for major equipment to ensure that research objectives can be met and biohazards can be contained, totaling $1,050,000 direct costs for Year 1 only.
8
NIH
National Heart, Lung, and Blood Institute (NHLBI)
Notice of Special Interest (NOSI) NOT-HL-20-757 issued by NHLBIDepending on parent awardSupplements of existing grants. Possible research interests include but are not limited to the following:
Host factors, including the microbiome or existing cardiac, respiratory, or hematologic conditions, that predispose persons to acquire SARS-CoV-2 or to develop severe COVID-19 disease, or that confer resistance to severe disease as in infants and young children
Manifestations, complications, and long-term consequences of SARS-CoV-2 infection, including identification of predictive biomarkers derived from imaging, clinical data, and biospecimens collected across organ systems
Time course and features of virus-host interactions, including the impact of SARS-CoV-2 infection on innate and adaptive immune responses
Prevalence and mechanisms of lung and cardiac injury with SARS-CoV-2 infection
Host factors and biological pathways that impact recovery and repair of the cardiopulmonary and vascular systems after SARS-CoV-2 infection
Development of animal or in vitro models of SARS-CoV-2 infection suitable for pathogenesis and therapeutic studies or transfusion transmission experiments such as, but not limited to, macaque and ACE-2 receptor murine models
Use of artificial intelligence or machine learning approaches to understand the biological pathways of COVID-19 disease, its comorbidities, and potential prevention strategies
Prevalence of RNAemia in symptomatic and asymptomatic people found to test positive for SARS-CoV-2 using respiratory tract samples
Dynamics of SARS-CoV-2 viremia and antibody response, and implications on screening and diagnostic assay development
Development of GMP quality hyper immune globulin from convalescent plasma collected from patients who have recovered from documented SARS-CoV-2 infection
Development and testing of strategies at the healthcare system level to address barriers and facilitators in the treatment of high-risk populations, particularly rural residents and underserved individuals
Supplementary funds may be used for the collection of blood or lung samples from human cohorts of individuals with COVID-19 or evidence of SARS-CoV-2 infection or controls, and/or development of novel model systems to expose animals and cells to SARS-CoV-2.
Up to parent grantNOSI specific for PA-18-591 (supplements)
Eligible activity codes are limited to the mechanisms (see link) + Application must have sufficient time left to complete the studies proposed after the supplement or revision has been awarded within the existing project period.
9
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
Notice of Special Interest (NOSI) NOT-AI-20-034 issued by NIAIDRollingRevisions of existing grants. Possible research interests include but are not limited to the following:
• Dev of reagents and assays for virus characterization;
• Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
• Studies to identify viral epitopes critical for binding neutralization;
• Production of molecular clones of 2019-nCoV, reporter viruses and recombinant viral proteins;
• Dev of sensitive, specific, and rapid clinical diagnostic tests for 2019-nCoV;
• Dev of 2019-nCoV therapeutic candidates; broad-spectrum therapeutics against multiple coronavirus strains; examination of 2019-nCoV antiviral activity of existing or candidate therapeutics initially developed for other indications;
Depending on parent grantApply through PA-20-135 mechanism (previously: NOSI specific for PA-18-935 (revisions). Eligible activity codes are limited to the following mechanisms: P01, R00, R01, R03, R15, R21, R33, R35, R41, R42, R43, R44, R61, U01, U24, U54, UG3, UH3, UM1)
10
Gates Foundation
Wellcome, Mastercard Foundation
COVID-19 Therapeutics AcceleratorTreatment.
Accelerating and evaluating new and repurposed drugs and biologics to treat patients.
$125M
11
National Institute of General Medical Sciences (NIGMS)Notice of Special Interest (NOSI) NOT-GM-20-025 issued by NIGMSRollingNIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:
1. Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
2. Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).
Depending on parent grantApplications in response to this NOSI must be submitted to PA-18-935 "Urgent Competitive Revision to Existing NIH Grants
12
NSFNSF 20-052non-medical, non-clinical-care research that can be used immediately to explore how
to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge
Proposals in response to this DCL may also request the use of NSF-funded advanced
computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream.
up to $200K and up
to one year in duration
Through existing NSF funding opportunities
13
AFWERX (US Air Force)Information collection of needs and solutions1. Combating the Spread (predictive analytics, next hotspot, threat to current activities, decision support, etc.)
2. Welfare of citizens (effects to transportation, movement of people and goods, education and development, physical training, regular HR functions, job transition, etc.)
3. Readiness (continuing operations through the outbreak, coordinating with allies and partners, continuing long term projects, etc.)
4. Logistics (security and protection, supply chain protection and assessment, etc.)
5. Industrial base impacts (small businesses, payments, contracts, large system programs, protection and expansion of critical assets, etc.)
6. Medical (telehealth, medical capacity and sustainment, medical supplies and equipment, etc.)
7. Other
Non-govermental and governmental solutions accepted
14
Consortium established by C3.ai and Microsoft, and led by UCB, UIUC,
Carnegie Mellon University, University of Chicago, MIT, and Princeton University
Call for Proposals5/1/2020 but better by April 15The Institute catalyzes cooperative research activities to accelerate advances in research, combining machine learning (ML), artificial intelligence (AI), the internet of things (IoT), management science, ethics, and public policy to transform and enhance the quality of life in societal systems at large.
Looking for bold proposals -- ethical questions, tech questions, diagnostics/therapeutics -- leveraging C3 platform.
- Modeling, analysis, of the spread
- Strenghen public health systems
- Minimize the spread
Costas Spanos from UCB is C3.ai DTI Chief Scientist.
Private fund from $100k (8), $250k (16) to $500k (2), use of the C3 AI software suite, and a significant amount of Microsoft Azure cloud computing time and scientific computing time as needed on NCSA/LBNL supercomputers
Project needs to be completed within a year
Favors projects using C3's computing platform
Prefer outcomes to be made pubicly available immediately.
No applications limit per PI
15
Agency for Healthcare Research and Quality (AHRQ)Notice of Intent NOT-HS-20-007TBDNew funding notice allowing requests for urgent revision supplements to existing AHRQ grants to address health system responsiveness to COVID-19. Depending on parent grant
Grant activity codes to be included or excluded from the funding notice will specified in the announcement.
16
Agency for Healthcare Research and Quality (AHRQ)Notice of Intent NOT-HS-20-008AHRQ is working to publish the FOA in early May 2020 with submissions due in June 2020.New funding opportunity announcement using the R01 mechanism to support novel, high-impact studies evaluating health system and healthcare professional responsiveness to COVID-19.
Funds critical research focused on innovations and challenges encountered in the rapid expansion of telemedicine in response to COVID-19, effects on quality, safety, and value of health system response to COVID-19, and the role of primary care practices and professionals during the COVID-19 epidemic. AHRQ is particularly interested in understanding how digital health innovations contributed to health system and healthcare professional innovation and challenges and solutions to meeting the needs of vulnerable populations including older adults, people living with multiple chronic conditions, rural communities, and uninsured and underinsured populations.
AHRQ expects to invest up to $5M in FY2020 funds to support this initiative and potentially more pending supplemental funding.
AHRQ will encourage multimethod, rapid-cycle research with the ability to produce and disseminate findings as early as 6 months.
17
The Schmidt Futures Tech + COVID19 groupPre-read document where you can describe what you are doing and what you needNext all-hands call will be on April 7A listserv for interested parties to flag two types of information: (a) requests for help (partners for emerging areas of interest; co-funding), (b) an offer of help (talent; funding; network), for others in the group. They would like to form 3-5 rapid-action working groups. Some possible topics (ventilators/supply shortages; rapid testing and tracing). They will circulate more information on the first set of rapid-action working groups shortly on the listserv. Ask for being added to the listserv
18
NASEM (George Strawn), ORFG (Open Research Funders Network that HHMI belongs to) and GO FAIR VODAN (Barend Mons)The GO FAIR Virus Outbreak Data Network (VODAN) They need subject specific experts (for example, virologists, epidemiologists, etc) who could vet/certify/review/annotate COVID19-related preprints. They need engineers to develop FAIR data repositories (FAIR data points) with ‘docking’ capabilities as a ‘station’ for ‘trains’ (virtual machines (VMs)) that come to ‘visit’ the data locally, with a specific question to ask. They need data scientists to interrogate the databases the network is linking out to. The databases include sequences of COVID19 variants, possible drug targets, clinical data and patient outcomes (in the form of electronic Clinical Research Forms (CRFs)) from across the globe.Those interested should sign up on the VODAN site (Contact form) to become an active participant and contributor. Others could be observers.
19
ConsortiumHigh Performance Computing ConsortiumThe Consortium is a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy and IBM to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines. Researchers are invited to submit COVID-19 related research proposals to the consortium.Access to computing resourcesa description, no longer than two pages, of your proposed work
20
NCATSNotice of Special Interest (NOSI) NOT-TR-20-011: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath NeedMay 4, 2020 for PA-18-591 mechanism (UL1, U01, R21 activity codes)

Later for others
Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).Depending on parent grant
21
CDCContract: Call for white papers2020, March 25Notice 75D301-20-R-67897
#1: Surveillance, natural history and household transmission of SARS CoV-2
#2: Diagnostics development and novel technology development and evaluation to improve diagnostic testing capabilities for COVID-19 detection
#3: Immune response and transmission dynamics for SARS CoV-2
#4: Host infection dynamics for SARS CoV-2
#5: Prospective Cohorts to Assess COVID-19 and Other Respiratory Diseases
Each white paper must adhere to all of the following requirements and should be no more than 4 pages in
length per subtopic area. The email subject line for the white paper shall include research topic number
and subtopic title.
• White Paper must be written in the following format:
a. Font size: 12-point, unreduced
b. Single-spaced
c. Paper size: 8.5 by 11 inches
d. Page Margin Size: One inch
e. Printed only on one side of page
f. Descriptive Title of the Proposed Project
g. BAA Number
• White paper submissions shall be unclassified.
BAA 75D301-20-R-67897
12
• Project description addressing in sufficient detail the characteristics identified in Part II. The offeror
may submit an individual white paper for any or all of the topic areas under Part II.
• Point of contact.
• A rough order of magnitude (ROM) cost estimate to implement the research effort.
• An estimated timeline to complete the project.
22
Medical CBRN Defense Consortium (MCDC) + Department of Defense’s (DoD) Solicitation2020, March 21 (recommended)
Open until 2020, May 31
White Papers with a focus on the following areas:
Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, and achieving Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) within the next one to four (1-4) months.
Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening. Any technology that can enhance the understanding of disease progression in COVID-19 infected patients is also of interest, including physiologic monitoring and other vital signs indicators, portable technology that enhances patient care in non-hospital settings, and technology that improves sample collection.
23
Medical CBRN Defense Consortium (MCDC) + Department of Defense’s (DoD) Solicitation (no specific link yet)2020, March 27RPP-20-04
Advance Treatment Based on Polyclonal Antibodies to Treat Coronavirus Disease 2019 (COVID-19) Response
24
AmazonAmazon’s Disaster ReliefProvides financial credits on the AWS cloud to help your research respond quickly to this critical community crisis
25
CDCSupplemental funding CDC-RFA-OT18-18020202SUPP20
April 2, 2020Only available to organizations that received funding under Funding Strategy 1 of CDC-RFA-OT18-1802: "Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health" in 2018.$1M
26
NIH
NIAID, NIA
PAR-20-139 Investigator Initiated Extended Clinical TrialMay 13, 2020 then September 13, 2020R01 Clinical Trial Required
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of one of the participating ICs.
27
NSF
Small Business Innovation Research (SBIR)
Small Business Innovation Research Program Phase I (SBIR)
Program solicitation NSF 20-527
NEXT submission window for Project Pitch closes JUNE 4, 2020Support research and development (R&D) of unproven, high-impact innovations, and development of deep technologies, based on discoveries in fundamental science and engineering for profound societal impacts
Phase I: 3-page project pitch
Phase II: full application
Phase I: up to $256k
Phase II: up to $1M
28
NSF
Small Business Technology Transfer (STTR)
Small Business Technology Transfer Program Phase I (STTR)
NSF-20-528
NEXT submission window for Project Pitch closes JUNE 4, 2020The NSF STTR program focuses on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental research, the NSF STTR program supports startups and small businesses in the creation of deep technologies, getting discoveries out of the lab and into the market.

The NSF STTR Program funds research and development. The program is designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development.
Phase I: up to $256k
Phase II: up to $1M
29
NSF
The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate
Request for SBIR/STTR Phase I Proposals Addressing COVID-19
NSF-20-065
Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.
30
Medical Technology Enterprise ConsortiumMTEC-Presolicitation-COVID-19April 15Potential areas of interest:
Point-of-care diagnostic that provides rapid and accurate determination on exposure to COVID-19.
Prophylactic(s)/Therapeutic(s) that can prevent and/or treat in a rapid manner (few hours to 2 days) potentially in a non-hospital environment. Repurposing FDA-approved drugs/biologics for prevention/treatment of COVID-19 or testing of drugs/biologics that have already demonstrated safety in humans for the prevention/treatment of COVID-19 are preferred.
Disease predictive modeling that provides early warning through data capture from several different streams of data to include social media and artificial intelligence (AI) parameter decision tools that would provide actionable information to medical service providers and command structures.
Patient monitoring, tracking, and management system for in-home or non-hospital environment patient tele-health services to include interface into the Cerner electronic health record.
MTEC believes that an emphasis will be placed on technologies that can be deployed as soon as possible but no later than 31 December 2020.
31
NSF
Computational and Data-Enabled Science and Engineering (CDS&E) or Cyberinfrastructure for Sustained Scientific Innovation (CSSI) programs
NSF 20-055 Provisioning Advanced Cyberinfrastructure to Further Research on COVID-19Complements NSF 20-052
RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.
Proposals in response to this DCL and the NSF DCL on COVID-19 (NSF 20-052) may also request the use of NSF-funded advanced computing resources such as Frontera, Stampede2, Bridges, Comet, and JetStream.

32
BARDA (Biomedical Advanced Research and Development Authority)BAA-20-100-SOL-0002, EZ BAA application process for diagnosticsMarch 18, 2020Focus area AOI #4: 2019-nCoV: development and Emergency Use Authorization (EUA) of an in vitro diagnostic assay for the detection of 2019-nCoV RNA in clinical specimens, including upper (e.g, nasopharyngeal and oropharyngeal swabs, nasopharyngeal wash/aspirate, or nasal aspirate) and lower (e.g., bronchoalveolar lavage, tracheal aspirate, or sputum) respiratory tract specimens. Up to $749kAbstract. Viable plan that achieves an EUA submission milestone within 12 weeks of award. Describe the current development status of your 2019-nCoV assay, including in silico analysis of targets, access to validation materials to support EUA submission, and contacts with the FDA.
33
BARDA (Biomedical Advanced Research and Development Authority)Portal: request a CoronaWatch meeting before submitting any application + apply onlineApril 30COVID-19 response related Areas of Interest includes:
7.7.1 Diagnostic assay for human coronavirus using existing FDA-cleared platforms
7.7.2 Point-of-care diagnostic assay for detection of SARS-CoV-2 virus
AOI 7.7.3 Diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
AOI 8.3 COVID-19 Vaccine
AOI 9.2 COVID-19 Therapeutics
AOI 9.3 Immunomodulators or therapeutics targeting lung repair
AOI 9.5 Pre-exposure and post-exposure prophylaxis
AOI 10 Respiratory protective devices
AOI 11 Ventilators
AOI 17 Advanced Manufacturing Technologies
34
Department of Energy (DOE)Leveraging DOE user facilities, computational resources, enabling infrastructureRollingResearch questions
35
Chan Zuckerberg Initiative (CZI) and Chan Zuckerberg Biohub
UCSF and Stanford University
COVID-19 Task ForceQuadruple the Bay Area’s COVID-19 testing and diagnostics capacitiesFunding acquisition of 2 state-of-the-the-art FDA approved clinical diagnostic machines
Increase UCSF's capabilties to diagnose
36
Ginkgo BioworksAccess to platformFunding towards projects that can use Ginkgo’s platform to accelerate development of point of care diagnostics, vaccines, or therapeutics.
Connection to sources of funding from private and public sources
$25M of no-cost foundry work
37
Natural Hazards CenterQuick Response Research Grant ProgramApril 1, 2020maximum five-page proposal (not including references)
Provides funds and training for eligible researchers to collect data in the aftermath of extreme events to document disaster before memories fade and physical evidence is erased.
How COVID-19 is affecting potentially vulnerable or marginalized populations, healthcare workers and other frontline responders, various organizations, and communities. Studies focused on policy responses, the economy, and other social consequences in the U.S. and globally are welcome and encouraged.
Funding notifications will be sent to all applicants no later than April 16.
Three to five research proposals of up to $3,000 will be funded.
38
In-PartOnline collaboration platformN/AFacilitates translation of reserach into commercialisation relating to combating COVID-19 directly (e.g. prophylactic or therapeutic vaccines, anti-viral drugs etc.) or indirectly (e.g. protective equipment, diagnostics etc.) White papers
39
Allen Institute for AI, Chan Zuckerberg Initiative (CZI), Georgetown U's Center for Security and Emerging Technology (CSET), Microsoft, and the National Library of Medicine (NLM) at the NIHCOVID-19 Open Research Dataset (CORD-19) of scholarly literature about COVID-19, SARS-CoV-2, and the Coronavirus groupN/AThe dataset represents the most extensive machine-readable Coronavirus literature collection available for data and text mining to date, with over 29,000 articles, more than 13,000 of which have full text.

Now, The White House joins these institutions in issuing a call to action to the Nation’s artificial intelligence experts to develop new text and data mining techniques that can help the science community answer high-priority scientific questions related to COVID-19.
Scholarly literature
40
FDA
NY State Department of Health
New policy allows laboratories to begin to use validated COVID-19 diagnostics before the FDA has completed review of the labs’ Emergency Use Authorization (EUA) requests
and allows other certified labs to test patient samples
Increase testing kits availabilityIntegrated DNA Technologies shipped 700,000 tests to commercial, academic and health care laboratories
Quest Diagnostics and LabCorp started making their own test kits
Many companies, hospitals and other institutions are now racing to develop more tests to diagnose
41
Coalition for Epidemic Preparedness Innovations Funding Vaccines R&DUp to now, $23.7M to Novavax, Inc., University of Oxford, Curevac Inc., Inovio Pharmaceuticals Inc., Moderna, Inc., and University of Queensland
42
Center for Disaster Philanthropy
Local NGOs
CDP COVID-19 Response FundSupport of healthcare workers
Support of quarantined and vulnerable populations
Support of hygiene promotion activities
43
Center for Disaster Philanthropy
UPS Foundation
Advocacy
Sharing accurate messaging
Funding preparedness, response and mitigation
Webinar
44
Seattle Foundation
United Way of King County
COVID-19 Response FundOne-time operating grants distributed to organizations that have deep roots in community and strong experience with disproportionately impacted communities
45
US government
FDA, Public Health and Social Services Emergency Fund
Public funding. Diverse initiatives.N/AFDA: support development of medical countermeasures and vaccines, and advanced manufacturing facilities for drugs.
PH and SSEF: development of countermeasures and vaccines, to expand US manufacturing capabilities, and for the purchase of vaccines, therapeutics, diagnostics.
$8.3B total:
$61M to FDA
$3.1B to PH and SSEF
$2.2B to Centers for Disease Control and Prevention to support federal, state and local public health agencies
$3B for R&D for vaccines, treatments and diagnostics
$1B for drugs, medical supplies and training
$500M for expanded telehealth services in Medicare
$1B in loan subsidies to help SMEs affected by the outbreak
$1.25B for foreign aid
46
WHO
United Nations Foundation, Swiss Philanthropy Foundation
COVID-19 Solidarity Response FundN/ASend essential supplies e.g. personal protective equipment to frontline health workers
Enable countries to track and detect the disease by boosting laboratory capacity through training and equipment
Ensure health workers and communities everywhere have access to the latest science-based information to protect themselves, prevent infection and care for those in need
Accelerate efforts to fast-track the discovery and development of lifesaving vaccines, diagnostics and treatments
As of March 13, $102M received
47
Genapsys, Foster City
Chinese Centers for Disease Control, Oxford Finance (financer)
New portable device for diagnosisN/ATesting a new and portable electronic device for DNA sequencing of the novel coronavirus$75M from Oxford Finance
48
UCSF
Mammoth Biosciences
"Rapid test" for COVIDN/ASimplify the diagnostic test for novel coronavirus, which could soon be used in walk in clinics.
49
WHOWorld Health Organization’s (WHO) COVID-19 R&D roadmapN/ADrawn up in a two-day meeting of 400 experts from around the world, sets out the gaps in knowledge about the virus and the priorities for future research
50
Innovative Medicines Initiative (IMI)
EU
FinancingN/AResearch on diagnostics, therapeutics and prevention€45M of Horizon 2020 money + €45M from private companies
51
Boston science (funded by China Evergrande Group)
Collaboration among 80 Boston researchers N/ALeads: Bruce Walker, director of the Ragon Institute of MGH, MIT, and Harvard with Arlene Sharpe, co-director of the Evergrande Center for Immunologic Diseases at Harvard Medical School and Brigham and Women’s Hospital
Build off a new repository of samples from infected people and community surveillance, materials that can be rapidly shared among scientists
$115M
52
Startup HealthCure Disease MoonshotN/APlatform to invest in innovators from around the world working on direct or indirect solutions for mitigating, managing, or treating coronavirus or future pandemicsPlatform not only dedicated to COVID
53
Gates Foundation
Gasthuisberg hospital at the University of Leuven
Therapeutics searchN/AProvide samples of 15,000 drug molecules to the hospital for screening in the search for therapeutics to treat COVID-19 infections.
54
Citadel, Chicago, IL
Citadel Securities
Medical suppliesN/ACritical medical supplies in Hubei and other regions affected in Cn7.5M
55
Squirrel AI LearningEducational coursesN/AOnline K-12 education courses across China free of charge$72.1 million worth of courses
56
Li Ka Shing FoundationMedical suppliesN/AMasks and safety gear for hospitals in HK250,000 masks to eldery in Hong Kong
57
GileadTreatmentN/AUse of existing Remdesivir, originally developed to treat the Ebola virus
58
RegeneronPrevention and treatmentN/AAntibody cocktail against viral proteins identified from its “VelocImmune” mouse technology (same approach it used to develop an Ebola vaccine and drug candidates to treat MERS, Dengue and Zika)
59
Novo Nordisk FoundationStrengthen Danish R&D for future new viral epidemicsN/AStrengthen Danish R&D for future new viral epidemics, noting the outbreak of the COVID-19 is not an isolated event i.e. fund interdisciplinary research including surveillance and early detection of viral infections; developing new technologies for preventing or controlling epidemics; and optimising national preparedness to manage new viral diseases, including developing policies and procedures for rapidly testing and approving new treatments, technologies and vaccines.€2.7M
60
Governments:
- China
- Canada
- Switzerland
- UK
- Germany
DonationsN/A- Donation to WHO
- Rapid Research Funding Opportunity competition through the Canadian Institutes of Health Research
- Swiss National Science Foundation
- UK National Institute for Health Research and the funding agency, UK Research and Innovation
- Germany’s Federal Ministry of Education and Research
China: $16B investment. $20M to WHO.
61
Canadian-based biotech Cyclica
Institute of Materia Medica in Beijing, Chinese Academy of Medical Sciences
CollaborationN/AMateria Medica conducts in vitro and in vivo antiviral assessment for molecules proposed by Cyclica
AI platform to discover antiviral drug candidates for COVID-19 by screening 6,700 FDA-approved drugs and drug candidates with at least Phase I clinical data against the structurally-characterized human proteome with a DL engine, MatchMakerTM, and explore opportunities to design multi-targeted antiviral compounds.
62
BioMerieuxDiagnosticsN/AbioMérieux has finalized the development of the SARS-COV-2 R-GENE® test. This real-time PCR test is clinically validated on one type of respiratory specimen and will be available at the end of March. It is expected to be rapidly CE marked and submitted to the FDA for an EUA (Emergency Use Authorization) as well.
Two BIOFIRE® tests will be submitted to relevant regulatory authorities in Q2 and Q3 2020 respectively, their launch will follow immediately after regulatory authorization or clearance.
N/A
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...